ATE241345T1 - Neue verwendung von orexinrezeptorantagonisten - Google Patents

Neue verwendung von orexinrezeptorantagonisten

Info

Publication number
ATE241345T1
ATE241345T1 AT00903690T AT00903690T ATE241345T1 AT E241345 T1 ATE241345 T1 AT E241345T1 AT 00903690 T AT00903690 T AT 00903690T AT 00903690 T AT00903690 T AT 00903690T AT E241345 T1 ATE241345 T1 AT E241345T1
Authority
AT
Austria
Prior art keywords
receptor antagonists
orexin receptor
new use
neuroprotectants
nausea
Prior art date
Application number
AT00903690T
Other languages
English (en)
Inventor
Elaine Alison Irving
Gareth John Sanger
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9903278.1A external-priority patent/GB9903278D0/en
Priority claimed from GBGB9903282.3A external-priority patent/GB9903282D0/en
Priority claimed from GBGB9903265.8A external-priority patent/GB9903265D0/en
Priority claimed from GBGB9903284.9A external-priority patent/GB9903284D0/en
Priority claimed from GBGB9906061.8A external-priority patent/GB9906061D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of ATE241345T1 publication Critical patent/ATE241345T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00903690T 1999-02-12 2000-02-10 Neue verwendung von orexinrezeptorantagonisten ATE241345T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9903278.1A GB9903278D0 (en) 1999-02-12 1999-02-12 Novel compounds
GBGB9903282.3A GB9903282D0 (en) 1999-02-12 1999-02-12 Novel use
GBGB9903265.8A GB9903265D0 (en) 1999-02-12 1999-02-12 Novel use
GBGB9903284.9A GB9903284D0 (en) 1999-02-12 1999-02-12 Novel use
GBGB9906061.8A GB9906061D0 (en) 1999-03-17 1999-03-17 Novel use
PCT/EP2000/001147 WO2000047284A2 (en) 1999-02-12 2000-02-10 Novel use of orexin receptor antagonists

Publications (1)

Publication Number Publication Date
ATE241345T1 true ATE241345T1 (de) 2003-06-15

Family

ID=27517496

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00903690T ATE241345T1 (de) 1999-02-12 2000-02-10 Neue verwendung von orexinrezeptorantagonisten

Country Status (8)

Country Link
US (1) US6506774B1 (de)
EP (2) EP1352651A3 (de)
JP (1) JP2002536425A (de)
AT (1) ATE241345T1 (de)
AU (1) AU2548400A (de)
DE (1) DE60002984T2 (de)
ES (1) ES2199770T3 (de)
WO (1) WO2000047284A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000047284A2 (en) * 1999-02-12 2000-08-17 Smithkline Beecham P.L.C. Novel use of orexin receptor antagonists
AU2001297807A1 (en) * 2000-12-20 2002-11-11 Sri International Modulators of the hypocretin system and methods of screening therefor
GB0126292D0 (en) * 2001-11-01 2002-01-02 Smithkline Beecham Plc Compounds
BRPI0508263B8 (pt) 2004-03-01 2021-05-25 Idorsia Pharmaceuticals Ltd derivados de 1, 2, 3, 4-tetra-hidro-isoquinolina, composição farmacêutica, e, uso de derivado de 1, 2, 3, 4-tetra-hidro-isoquinolina
FR2896798A1 (fr) 2006-01-27 2007-08-03 Sanofi Aventis Sa Derives de sulfonamides, leur preparation et leur application en therapeutique
FR2896799B1 (fr) 2006-02-02 2008-03-28 Sanofi Aventis Sa Derives de sulfonamides, leur preparation et leur application en therapeutique
WO2015048091A1 (en) * 2013-09-24 2015-04-02 The Board Of Regents Of The University Of Texas System Orexin-control of bone formation and loss
US20190083508A1 (en) * 2014-11-24 2019-03-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Use of ox1r antagonists for the treatment of inflammatory bowel diseases
CN111051295B (zh) 2017-08-03 2022-09-02 武田药品工业株式会社 杂环化合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2220036A1 (en) * 1995-05-05 1996-11-07 Human Genome Sciences, Inc. Human neuropeptide receptor
US6309854B1 (en) 1996-12-17 2001-10-30 Smithkline Beecham Corporation Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72
US6020157A (en) * 1997-04-30 2000-02-01 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72X receptor
US5935814A (en) * 1997-04-30 1999-08-10 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72Y receptor
US6166193A (en) * 1997-07-25 2000-12-26 Board Of Regents, University Of Texas System Polynucleotides encoding MY1 receptor
AR016817A1 (es) * 1997-08-14 2001-08-01 Smithkline Beecham Plc Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento
WO1999030670A2 (en) * 1997-12-15 1999-06-24 Smithkline Beecham Plc Methods of treatment using novel ligands of the neuropeptide receptor hfgan72 and agonists or antagonists thereof
US6372757B1 (en) 1998-05-08 2002-04-16 Smithkline Beecham P.L.C. Phenylurea and phenylthio urea derivatives
ES2255330T3 (es) 1998-11-10 2006-06-16 MERCK &amp; CO., INC. Espiroindolinas como antagonistas del receptor y5.
WO2000047284A2 (en) * 1999-02-12 2000-08-17 Smithkline Beecham P.L.C. Novel use of orexin receptor antagonists
US6596730B1 (en) * 1999-02-12 2003-07-22 Smithkline Beecham P.L.C. Phenyl urea and phenyl thiourea derivatives

Also Published As

Publication number Publication date
US6506774B1 (en) 2003-01-14
ES2199770T3 (es) 2004-03-01
DE60002984D1 (de) 2003-07-03
JP2002536425A (ja) 2002-10-29
EP1150664A2 (de) 2001-11-07
EP1352651A3 (de) 2003-11-12
DE60002984T2 (de) 2004-03-11
AU2548400A (en) 2000-08-29
WO2000047284A3 (en) 2000-12-14
EP1150664B1 (de) 2003-05-28
WO2000047284A2 (en) 2000-08-17
EP1352651A2 (de) 2003-10-15

Similar Documents

Publication Publication Date Title
DE69929235D1 (de) Spiro-indole als y5-rezeptor antagonisten
ATE360032T1 (de) Cystein-reiche rezeptoren-train
ATE242243T1 (de) Zyklische verbindungen, ihre herstellung und ihre verwendung als tachykininrezeptorantagonisten
DE69943352D1 (de) Azabicycloalkane als ccr5-modulatoren
BR9707391A (pt) Pirazolpirimidinas como antagonistas de receptor de crf
AP2000001949A0 (en) 4-Benzyl piperidine alkysulfoxide heterocycles and their use as subtype-selective NMDA receptor antagonists.
DZ2618A1 (fr) Emploi des antagonistes des récepteurs de 5-HT3 dans le traitement de la colopathie.
TR199801255T2 (xx) Vitronektin resept�r antagonistleri.
TR970073A2 (tr) Alfa adrenerjik resentör antagonistleri olarak pirimidindion pirimidintrion,triazindion, tetrahidrokinazolindion türevleri.
ATE312819T1 (de) 4,4-biarylpiperidinederivate mit opioid-receptor- wirkung
BR9704117B1 (pt) derivados de insulina com maior ligação com zinco.
ITTO991021A0 (it) Antagonisti ii del recettore ccr-3.
PT885215E (pt) Novos derivados de pirrolidina substituidos com benzo-1,3-dioxolilo e benzofuranilo como antagonistas de endotelina
IT1318319B1 (it) Composizione di gomma, procedimento per produrre la stessa e manicottoutilizzante la composizione di gomma.
ATE194595T1 (de) Benzonitrile als 5-ht agonisten und antagonisten
DK1021541T3 (da) Aminoterminalt trunkeret MCP-2 som chemokinantagonister
DE69128941T2 (de) Verwendung von angiotensin-ii-rezeptorantagonisten in der behandlung der diabetischen nephropathie
AU1667500A (en) N-(2-phenyl-4-piperidinybutyl)-5,6,7,8-tetrahydro-1-naphthal necarboxamides and their use as neurokinin 1 (nk1) and/or neurokinin 2 (nk2) receptor antagonists
ATE241345T1 (de) Neue verwendung von orexinrezeptorantagonisten
DE60024652D1 (de) Unkonjugiertes cyklisches polyencopolymer, kautschukzusammensetzung und verwendung
DE69718786D1 (de) Benzoxazinone als dopamine -d4- rezeptor-antagonisten
DE69740099D1 (de) Transdermale zusammenstellung mit serotoninrezeptor-antagonist
DE10017774B4 (de) Befestigungsplatte, Befestigungsanordnung mit der Befestigungsplatte und Verwendung der Befestigungsplatte
PT923550E (pt) Derivados de acilaminoalcenileno-amida como antagonistas de nk1 e nk2
PT1200400E (pt) Derivados de pirrolidino-2,3,4-trion-3-oxina substituidas com eficacia como antagonistas do receptor nmda

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties